• 1.

    WHO, 2011. The Global Plan to STOP TB 2011–2015.Geneva:World Health Organization, (WHO/HTM/STB/2010.2).

  • 2.

    Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD, 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralized use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 14951505.

    • Search Google Scholar
    • Export Citation
  • 3.

    Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, Deng S, Chen M, 2012.Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 64: 580588.

    • Search Google Scholar
    • Export Citation
  • 4.

    Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD, 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 10051015.

    • Search Google Scholar
    • Export Citation
  • 5.

    Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R, 2011. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8: e1001067.

    • Search Google Scholar
    • Export Citation
  • 6.

    Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, Boehme CC, Zemanay W, Zar HJ, 2011. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 11: 819824.

    • Search Google Scholar
    • Export Citation
  • 7.

    Rachow A, Clowes P, Saathoff E, Mtafya B, Michael E, Ntinginya EN, Kowour D, Rojas-Ponce G, Kroidl A, Maboko L, Heinrich N, Reither K, Hoelscher M, 2012. Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis 54: 13881396.

    • Search Google Scholar
    • Export Citation
  • 8.

    Hillemann D, Rusch-Gerdes S, Boehme C, Richter E, 2011. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol 49: 12021205.

    • Search Google Scholar
    • Export Citation
  • 9.

    Ligthelm LJ, Nicol MP, Hoek KG, Jacobson R, van Helden PD, Marais BJ, Warren RM, Wright CA, 2011. Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. J Clin Microbiol 49: 39673970.

    • Search Google Scholar
    • Export Citation
  • 10.

    Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal MP, Pascarella M, Borroni E, Mondo A, Piana F, Scarparo C, Coltella L, Lombardi G, Cirillo DM, 2012. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012 Jan 12 [Epub ahead of print].

    • Search Google Scholar
    • Export Citation
  • 11.

    Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C, 2011. Xpert MTB/RIF, a new pillar in the diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 49: 25402545.

    • Search Google Scholar
    • Export Citation
  • 12.

    Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, Khaliqov A, Zamudio C, Perkins MD, Boehme CC, Cobelens F, 2011. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 8: e1001120.

    • Search Google Scholar
    • Export Citation
  • 13.

    Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, Wiktor SZ, 1999. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2012: 11.

    • Search Google Scholar
    • Export Citation
  • 14.

    Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, Freedberg KA, Walensky RP, 2012. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy in South Africa: a model-based analysis. AIDS 26: 987995.

    • Search Google Scholar
    • Export Citation
  • 15.

    Floyd K, Pantoja A, Glasziou P, 2010. Xpert MTB/RIF in the Global Plan 2011–2015. What Will It Cost? Geneva: World Health Organization Global Consultation on Xpert implementation.

    • Search Google Scholar
    • Export Citation
  • 16.

    WHO, 2011. Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. Geneva: World Health Organization, (WHO/HTM/TB/2011.4).

    • Search Google Scholar
    • Export Citation
  • 17.

    WHO, 2011. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test: Technical and Operational “How-to”; Practical Considerations. Geneva: World Health Organization, (WHO/HTM/TB/2011.2).

    • Search Google Scholar
    • Export Citation
  • 18.

    WHO, 2011. Checklist of Prerequisites to Country Implementation of Xpert MTB/RIF and Key Action Points at Country Level. Geneva: World Health Organization, (WHO/HTM/TB/2011.12).

    • Search Google Scholar
    • Export Citation
 
 
 

 

 
 
 

 

 

 

 

 

 

Transforming TB Diagnosis: Can Patients and Control Programs Afford to Wait?

View More View Less
  • Dartmouth College, Hanover, New Hampshire; GHESKIO, Port-au-Prince, Haiti; Weill Cornell Medical College, New York, New York; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

Author Notes

*Address correspondence to Catharina C. Boehme, 16, Av de Budé, Geneva 1202. E-mail: Catharina.Boehme@finddiagnostics.org

Disclosure: Mark D. Perkins, Lakshmi Sundaram, and Catharina C. Boehme are employed by FIND, a non-profit that collaborates with industry partners, including Cepheid, Inc., the manufacturer of Xpert MTB/RIF, for the development, evaluation, and demonstration of new diagnostic tests for poverty-related diseases. This statement is made in the interest of full disclosure and not because the authors consider this to be a conflict of interest.

Authors' addresses: Elizabeth A. Talbot, Infectious Disease and International Health, Dartmouth College, Hanover, NH, E-mail: Elizabeth.Talbot@dartmouth.edu. Jean W. Pape, Center for Global Health, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY; and Les Centres GHESKIO, Port-au-Prince, Haiti, E-mail: JWPape@gheskio.org. Lakshmi Sundaram, Catharina C. Boehme, and Mark D. Perkins, Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland, E-mails: Lakshmi.Sundaram@finddiagnostics.org, Catharina.Boehme@finddiagnostics.org and Mark.Perkins@finddiagnostics.org.

Save